



## **G1 Therapeutics to Participate in the Evercore ISI 3rd Annual HealthCONx Conference on December 3, 2020**

November 24, 2020

RESEARCH TRIANGLE PARK, N.C., Nov. 24, 2020 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: [GTHX](#)), a clinical-stage oncology company, today announced that incoming Chief Executive Officer Jack Bailey and Chief Medical Officer and Senior Vice President, R&D Raj Malik, M.D. will present a company update at the Evercore ISI 3<sup>rd</sup> Annual HealthCONx Conference on December 3, 2020 at 1:00 p.m. ET.

To access the live and archived webcast of the presentation, please visit the [Events & Presentations page](#) of the [G1 website](#).

### **About G1 Therapeutics**

G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and delivery of next generation therapies that improve the lives of those affected by cancer. The company is developing and advancing two novel therapies: [trilaciclib](#) is a first-in-class therapy designed to improve outcomes for patients being treated with chemotherapy; [rintodestrant](#) is a potential best-in-class oral selective estrogen receptor degrader (SERD) for the treatment of ER+ breast cancer. In 2020, the company out-licensed global development and commercialization rights to its differentiated oral CDK4/6 inhibitor, lerociclib.

G1 Therapeutics is based in Research Triangle Park, N.C. For additional information, please visit [www.g1therapeutics.com](http://www.g1therapeutics.com) and follow us on Twitter [@G1Therapeutics](#).

### **Contact:**

Jeff Macdonald  
G1 Therapeutics, Inc.  
Senior Director, Investor Relations & Corporate Communications  
919-907-1944  
[jmacdonald@g1therapeutics.com](mailto:jmacdonald@g1therapeutics.com)



Source: G1 Therapeutics